Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
HRpos/HER2neg first-line MBC patients have a more favorable prognosis if the disease was previously not treated. This difference was similar across all examined clinicopathological parameters. It may therefore be beneficial to incorporate MBC categories as a stratification factor in clinical trials.
Authors
- Michael Untch (ORCID: https://orcid.org/0000-0002-1233-1267)
- Hanna Huebner (ORCID: https://orcid.org/0000-0001-6889-1493)
- Florin‐Andrei Taran (ORCID: https://orcid.org/0000-0001-9167-047X)
- Carsten Hielscher
- Laura L. Michel (ORCID: https://orcid.org/0000-0002-7784-2826)
- Christian M. Kurbacher
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Hans‐Christian Kolberg (ORCID: https://orcid.org/0000-0003-0221-3272)
- Sara Y. Brucker (ORCID: https://orcid.org/0000-0001-5162-1542)
- Markus Wallwiener (ORCID: https://orcid.org/0000-0002-4139-9340)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Rachel Wuerstlein (ORCID: https://orcid.org/0000-0001-7268-0840)
- D. Wallwiener (ORCID: https://orcid.org/0000-0002-4635-5283)
- Diana Lüftner (ORCID: https://orcid.org/0000-0003-2511-9115)
- Christoph Mundhenke (ORCID: https://orcid.org/0000-0002-6989-6250)
- Lothar Häberle (ORCID: https://orcid.org/0000-0003-4019-9328)
- Julia Meyer (ORCID: https://orcid.org/0000-0002-1356-7597)
- Erik Belleville
- Matthias W. Beckmann (ORCID: https://orcid.org/0000-0002-8441-693X)
- Wolfgang Janni (ORCID: https://orcid.org/0000-0001-5911-2400)
- Johannes Ettl (ORCID: https://orcid.org/0000-0003-4754-8447)
- Carlo Fremd (ORCID: https://orcid.org/0000-0002-7840-430X)
- Pauline Wimberger (ORCID: https://orcid.org/0000-0002-7380-577X)
- Michael P. Lux (ORCID: https://orcid.org/0000-0002-2781-2178)
- Sabrina Uhrig
- Peyman Hadji (ORCID: https://orcid.org/0000-0003-4787-3151)
- Hans Tesch (ORCID: https://orcid.org/0000-0001-7839-4917)
- Alexander Hein (ORCID: https://orcid.org/0000-0003-2601-3398)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Christina Barbara Walter (ORCID: https://orcid.org/0000-0002-3059-7595)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Chloë Goossens (ORCID: https://orcid.org/0000-0002-0999-8562)
- Volkmar Müller (ORCID: https://orcid.org/0000-0002-6386-0900)
Institutions
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Medical Center Freiburg (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Heidelberg (DE)
- Kempten University of Applied Sciences (DE)
- LMU Klinikum (DE)
- Universitätsklinikum Erlangen (DE)
- Cardiovascular Center Bethanien (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- Marienhospital Bottrop (DE)
- Breast Center (CH)
- Cardiovascular Center Frankfurt (DE)
- Brüderkrankenhaus St. Josef Paderborn (DE)
- University of Applied Sciences Stralsund (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Hospital in Halle (DE)
- Immanuel Krankenhaus (DE)
- University Hospital Ulm (DE)
- Helios Hospital Berlin-Buch (DE)
- University Hospital Carl Gustav Carus (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Tübingen (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- The Breast
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1016/j.breast.2025.104412
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Roche
- Celgene
- Hexal AG
- Daiichi-Sankyo
- Eisai
- Novartis Pharma
- Eisai Incorporated
- Daiichi Sankyo Europe